{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:07:06Z","timestamp":1792242426031,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40264-026-01670-w","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:40:05Z","timestamp":1775810405000},"page":"969-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer\u2019s Disease: Timing and Duration of Adverse Events"],"prefix":"10.1007","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct01862640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01922258","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03548584","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03594123","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Anton P.","family":"Porsteinsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5882-0920","authenticated-orcid":false,"given":"Sanjeda R.","family":"Chumki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Such","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton M.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwa","family":"Kalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Brendan","family":"Montano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"7","key":"1670_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology. 1984;34(7):939\u201344. https:\/\/doi.org\/10.1212\/wnl.34.7.939.","journal-title":"Neurology"},{"issue":"3","key":"1670_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gps.5030","volume":"34","author":"R Halpern","year":"2019","unstructured":"Halpern R, Seare J, Tong J, Hartry A, Olaoye A, Aigbogun MS. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia. Int J Geriatr Psychiatry. 2019;34(3):420\u201331. https:\/\/doi.org\/10.1002\/gps.5030.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"1670_CR3","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/gps.5604","volume":"36","author":"H Fillit","year":"2021","unstructured":"Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, et al. Impact of agitation in long-term care residents with dementia in the United States. Int J Geriatr Psychiatry. 2021;36(12):1959\u201369. https:\/\/doi.org\/10.1002\/gps.5604.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"1670_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1017\/S1041610222001041","volume":"36","author":"M Sano","year":"2024","unstructured":"Sano M, Cummings J, Auer S, Bergh S, Fischer CE, Gerritsen D, et al. Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition. Int Psychogeriatr. 2024;36(4):238\u201350. https:\/\/doi.org\/10.1017\/S1041610222001041.","journal-title":"Int Psychogeriatr"},{"issue":"5","key":"1670_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","volume":"172","author":"ME Peters","year":"2015","unstructured":"Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460\u20135. https:\/\/doi.org\/10.1176\/appi.ajp.2014.14040480.","journal-title":"Am J Psychiatry"},{"key":"1670_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.trci.2019.10.004","volume":"5","author":"M Cloutier","year":"2019","unstructured":"Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, et al. Institutionalization risk and costs associated with agitation in Alzheimer\u2019s disease. Alzheimers Dement NY. 2019;5:851\u201361. https:\/\/doi.org\/10.1016\/j.trci.2019.10.004.","journal-title":"Alzheimers Dement NY"},{"issue":"4","key":"1670_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1192\/bjpo.bp.117.005181","volume":"3","author":"G Livingston","year":"2017","unstructured":"Livingston G, Barber J, Marston L, Rapaport P, Livingston D, Cousins S, et al. Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study. BJPsych Open. 2017;3(4):171\u20138. https:\/\/doi.org\/10.1192\/bjpo.bp.117.005181.","journal-title":"BJPsych Open"},{"issue":"2","key":"1670_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1532-5415.2009.02680.x","volume":"58","author":"T Okura","year":"2010","unstructured":"Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the Aging, Demographics, and Memory Study. J Am Geriatr Soc. 2010;58(2):330\u20137. https:\/\/doi.org\/10.1111\/j.1532-5415.2009.02680.x.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"1670_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3233\/JAD-215670","volume":"88","author":"J Schein","year":"2022","unstructured":"Schein J, Houle CR, Urganus AL, Jones E, Pike J, Husbands J, et al. The impact of agitation in dementia on caregivers: a real-world survey. J Alzheimers Dis. 2022;88(2):663\u201377. https:\/\/doi.org\/10.3233\/JAD-215670.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"1670_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1517\/14656566.2015.1059422","volume":"16","author":"IM Antonsdottir","year":"2015","unstructured":"Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP. Advancements in the treatment of agitation in Alzheimer\u2019s disease. Expert Opin Pharmacother. 2015;16(11):1649\u201356. https:\/\/doi.org\/10.1517\/14656566.2015.1059422.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1670_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3233\/jad-200127","volume":"77","author":"MS Aigbogun","year":"2020","unstructured":"Aigbogun MS, Cloutier M, Gauthier-Loiselle M, Guerin A, Ladouceur M, Baker RA, et al. Real-world treatment patterns and characteristics among patients with agitation and dementia in the United States: findings from a large, observational, retrospective chart review. J Alzheimers Dis. 2020;77(3):1181\u201394. https:\/\/doi.org\/10.3233\/jad-200127.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1670_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229\u201345. https:\/\/doi.org\/10.1177\/2040622316658463.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"1670_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/00325481.2025.2517535","volume":"137","author":"GT Grossberg","year":"2025","unstructured":"Grossberg GT, Sanford A, Montano CB, Porsteinsson AP, Scanland S, Worz C, et al. A US-based practitioner\u2019s guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer\u2019s dementia\u2014recommendations of an expert, multispecialty advisory panel. Postgrad Med. 2025;137(6):469\u201385. https:\/\/doi.org\/10.1080\/00325481.2025.2517535.","journal-title":"Postgrad Med"},{"issue":"1","key":"1670_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","volume":"40","author":"M Rogowska","year":"2023","unstructured":"Rogowska M, Thornton M, Creese B, Velayudhan L, Aarsland D, Ballard C, et al. Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011\u20132022 update. Drugs Aging. 2023;40(1):21\u201332. https:\/\/doi.org\/10.1007\/s40266-022-00992-5.","journal-title":"Drugs Aging"},{"issue":"5","key":"1670_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/sj.npp.1301492","volume":"33","author":"DV Jeste","year":"2008","unstructured":"Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957\u201370. https:\/\/doi.org\/10.1038\/sj.npp.1301492.","journal-title":"Neuropsychopharmacology"},{"issue":"15","key":"1670_CR16","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u201343. https:\/\/doi.org\/10.1001\/jama.294.15.1934.","journal-title":"JAMA"},{"issue":"3","key":"1670_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0828","volume":"2","author":"I Yunusa","year":"2019","unstructured":"Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019;2(3):e190828. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0828.","journal-title":"JAMA Netw Open"},{"key":"1670_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076268","volume":"385","author":"PLH Mok","year":"2024","unstructured":"Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268. https:\/\/doi.org\/10.1136\/bmj-2023-076268.","journal-title":"BMJ"},{"issue":"3","key":"1670_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/jad-140579","volume":"42","author":"H Ma","year":"2014","unstructured":"Ma H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915\u201337. https:\/\/doi.org\/10.3233\/jad-140579.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1670_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2014.6930","volume":"175","author":"LA Fraser","year":"2015","unstructured":"Fraser LA, Liu K, Naylor KL, Hwang YJ, Dixon SN, Shariff SZ, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450\u20132. https:\/\/doi.org\/10.1001\/jamainternmed.2014.6930.","journal-title":"JAMA Intern Med"},{"issue":"15","key":"1670_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med. 2006;355(15):1525\u201338. https:\/\/doi.org\/10.1056\/NEJMoa061240.","journal-title":"N Engl J Med"},{"issue":"3","key":"1670_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191\u2013210. https:\/\/doi.org\/10.1097\/01.JGP.0000200589.01396.6d.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1670_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3389\/fphar.2020.00596","volume":"11","author":"I Yunusa","year":"2020","unstructured":"Yunusa I, El Helou ML. The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use. Front Pharmacol. 2020;11:596. https:\/\/doi.org\/10.3389\/fphar.2020.00596.","journal-title":"Front Pharmacol"},{"key":"1670_CR24","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti\u00ae (brexpiprazole) tablets, for oral use. Prescribing information [United States] 2025. https:\/\/www.otsuka-us.com\/media\/static\/Rexulti-PI.pdf. Accessed 13 June 2025."},{"key":"1670_CR25","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti\u00ae brexpiprazole tablets. Product monograph [Canada] 2024. https:\/\/rexultimonograph.ca\/. Accessed 13 June 2025."},{"issue":"4","key":"1670_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"GT Grossberg","year":"2020","unstructured":"Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383\u2013400. https:\/\/doi.org\/10.1016\/j.jagp.2019.09.009.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"1670_CR27","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","volume":"80","author":"D Lee","year":"2023","unstructured":"Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, Kohegyi E, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307\u201316. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3810.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1670_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40261-025-01517-9","volume":"46","author":"JL Cummings","year":"2026","unstructured":"Cummings JL, Chumki SR, Chang D, Zhang Z, Brubaker M, Hefting N, et al. Efficacy of brexpiprazole in participants with agitation associated with dementia due to Alzheimer\u2019s disease: pooled analysis of randomized controlled trials. Clin Drug Investig. 2026;46(3):281\u201392. https:\/\/doi.org\/10.1007\/s40261-025-01517-9.","journal-title":"Clin Drug Investig"},{"key":"1670_CR29","doi-asserted-by":"publisher","first-page":"1379062","DOI":"10.3389\/fneur.2024.1379062","volume":"15","author":"J Meunier","year":"2024","unstructured":"Meunier J, Creel K, Loubert A, Larsen KG, Aggarwal J, Hefting N, et al. Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer\u2019s dementia. Front Neurol. 2024;15:1379062. https:\/\/doi.org\/10.3389\/fneur.2024.1379062.","journal-title":"Front Neurol"},{"key":"1670_CR30","doi-asserted-by":"publisher","first-page":"891988725140712","DOI":"10.1177\/08919887251407124","volume":"2025","author":"GT Grossberg","year":"2025","unstructured":"Grossberg GT, Sabbagh MN, Chumki SR, Wang D, Such P, Zhang Z, et al. Efficacy of brexpiprazole on neuropsychiatric symptoms and impact on caregivers: pooled Neuropsychiatric Inventory (NPI) analysis in patients with agitation associated with dementia due to Alzheimer\u2019s disease. J Geriatr Psychiatry Neurol. 2025:8919887251407124. https:\/\/doi.org\/10.1177\/08919887251407124.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"10","key":"1670_CR31","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40263-025-01200-9","volume":"39","author":"A Shah","year":"2025","unstructured":"Shah A, Estilo A, Sheridan PL, Kalu U, Chen D, Chang D, et al. Safety and tolerability of brexpiprazole in participants with agitation associated with dementia due to Alzheimer\u2019s disease: pooled analysis of three randomized trials and an extension trial. CNS Drugs. 2025;39(10):1011\u201323. https:\/\/doi.org\/10.1007\/s40263-025-01200-9.","journal-title":"CNS Drugs"},{"issue":"2","key":"1670_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3233\/JAD-240491","volume":"102","author":"S Behl","year":"2024","unstructured":"Behl S, Slomkowski M, Chen D, Chang D, Hefting N, Lee D, et al. Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer\u2019s disease: a 12-week, active-treatment, extension trial. J Alzheimers Dis. 2024;102(2):520\u20139. https:\/\/doi.org\/10.3233\/JAD-240491.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1670_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"1670_CR34","unstructured":"Cummings JL. Neuropsychiatric Inventory Nursing Home Version (NPI-NH): comprehensive assessment of psychopathology in patients with dementia residing in Nursing Homes. 2009."},{"issue":"12","key":"1670_CR35","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/wnl.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308\u201314. https:\/\/doi.org\/10.1212\/wnl.44.12.2308.","journal-title":"Neurology"},{"issue":"11","key":"1670_CR36","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1176\/appi.ajgp.13.11.991","volume":"13","author":"J Rabinowitz","year":"2005","unstructured":"Rabinowitz J, Davidson M, De Deyn PP, Katz I, Brodaty H, Cohen-Mansfield J. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005;13(11):991\u20138. https:\/\/doi.org\/10.1176\/appi.ajgp.13.11.991.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1670_CR37","volume-title":"Instruction manual for the Cohen-Mansfield Agitation Inventory (CMAI)","author":"J Cohen-Mansfield","year":"1991","unstructured":"Cohen-Mansfield J. Instruction manual for the Cohen-Mansfield Agitation Inventory (CMAI). Rockville: The Research Institute of the Hebrew Home of Greater Washington; 1991."},{"issue":"3","key":"1670_CR38","doi-asserted-by":"publisher","first-page":"M77","DOI":"10.1093\/geronj\/44.3.m77","volume":"44","author":"J Cohen-Mansfield","year":"1989","unstructured":"Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):M77-84. https:\/\/doi.org\/10.1093\/geronj\/44.3.m77.","journal-title":"J Gerontol"},{"key":"1670_CR39","volume-title":"ECDEU assessment manual for psychopharmacology, revised","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville: National Institute of Mental Health; 1976."},{"issue":"9","key":"1670_CR40","doi-asserted-by":"publisher","first-page":"afae177","DOI":"10.1093\/ageing\/afae177","volume":"53","author":"Y Li","year":"2024","unstructured":"Li Y, Smith RM, Whitney SL, Seemungal BM, Ellmers TJ. Association between dizziness and future falls and fall-related injuries in older adults: a systematic review and meta-analysis. Age Ageing. 2024:53(9):afae177. https:\/\/doi.org\/10.1093\/ageing\/afae177.","journal-title":"Age Ageing"},{"issue":"3","key":"1670_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","volume":"143","author":"JT Rich","year":"2010","unstructured":"Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan\u2013Meier curves. Otolaryngol Head Neck Surg. 2010;143(3):331\u20136. https:\/\/doi.org\/10.1016\/j.otohns.2010.05.007.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"1670_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34(2):187\u2013202. https:\/\/doi.org\/10.1111\/j.2517-6161.1972.tb00899.x.","journal-title":"J R Stat Soc B"},{"issue":"3","key":"1670_CR43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin\u2013dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604. https:\/\/doi.org\/10.1124\/jpet.114.213793.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"1670_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28918","volume":"10","author":"Y Du","year":"2024","unstructured":"Du Y, Li Q, Dou Y, Wang M, Wang Y, Yan Y, et al. Side effects and cognitive benefits of buspirone: a systematic review and meta-analysis. Heliyon. 2024;10(7):e28918. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28918.","journal-title":"Heliyon"},{"issue":"2","key":"1670_CR45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","volume":"135","author":"JY Leung","year":"2012","unstructured":"Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther. 2012;135(2):113\u201322. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.04.003.","journal-title":"Pharmacol Ther"},{"issue":"Suppl 2","key":"1670_CR46","first-page":"3","volume":"6","author":"DD Miller","year":"2004","unstructured":"Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):3\u20137.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"8","key":"1670_CR47","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/03007995.2025.2552278","volume":"41","author":"J Stroud","year":"2025","unstructured":"Stroud J, Cummings JL, Chumki SR, Such P, Wang D, Palma AM, et al. Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer\u2019s disease. Curr Med Res Opin. 2025;41(8):1523\u201334. https:\/\/doi.org\/10.1080\/03007995.2025.2552278.","journal-title":"Curr Med Res Opin"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01670-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01670-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01670-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:02:20Z","timestamp":1783702940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01670-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01670-w","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"APP has received personal fees from Acadia Pharmaceuticals, Athira, Axsome, Biogen, BMS, Cognitive Research Corp, Cognition Therapeutics, Eisai, IQVIA, Lundbeck, MapLight Therapeutics, Novartis, Novo Nordisk, Oligomerix, ONO Pharmaceuticals, Otsuka, WCG, WebMD, and Xenon; and his institution has received grants from Athira, Biogen, Cassava, Eisai, Eli Lilly, Genentech\/Roche, Vaccinex, NIA, NIMH, and DOD. He is a member of the Scientific Advisory Board of Alzheon, Athira, Cognition Therapeutics, and Oligomerix. SRC, AMP, ZZ, and AS are full-time employees of Otsuka Pharmaceutical Development & Commercialization Inc. DW and UK are full-time employees of Lundbeck LLC. PS is a full-time employee of H. Lundbeck A\/S. CBM has received consulting fees from AbbVie, Acadia Pharmaceuticals, Alkermes, Arbor, Eisai, Neos, Novo Nordisk, Otsuka, Sunovion, Supernus, and Takeda, and has received payment\/honoraria from AbbVie, Arbor, Eisai, Otsuka, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (post hoc analysis).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable (post hoc analysis).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"To submit inquiries related to Otsuka clinical research, or to request access to individual participant data (IPD) associated with any Otsuka clinical trial, please visit\n                      \n                      . For all approved IPD access requests, Otsuka will share anonymized IPD on a remotely accessible data sharing platform.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"APP: Conceptualization; methodology; writing \u2013 review and editing. SRC: Conceptualization; methodology; supervision; writing \u2013 review and editing. DW: Conceptualization; methodology; supervision; writing \u2013 review and editing. PS: Conceptualization; methodology; supervision; writing \u2013 review and editing. AMP: Conceptualization; data curation; formal analysis; investigation; methodology; software; validation; visualization; writing \u2013 review and editing. ZZ: Conceptualization; data curation; formal analysis; investigation; methodology; software; validation; visualization; writing \u2013 review and editing. AS: Methodology; Writing \u2013 review and editing. UK: Methodology; writing \u2013 review and editing. CBM: Conceptualization; methodology; writing \u2013 review and editing. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}